A Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis
Phase of Trial: Phase III
Latest Information Update: 09 Dec 2016
At a glance
- Drugs RVL 1201 (Primary)
- Indications Blepharoptosis
- Focus Therapeutic Use
- Sponsors RevitaLid
- 06 Dec 2016 Status changed from active, no longer recruiting to completed.
- 24 Oct 2016 Planned End Date changed from 1 Jun 2016 to 1 Nov 2016.
- 24 Oct 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Nov 2016.